# A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus Erythematosus

> **NCT04493541** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 13 (actual)

## Conditions studied

- Lupus Erythematosus, Cutaneous

## Interventions

- **DRUG:** BMS-986256
- **OTHER:** BMS-986256 Placebo

## Key facts

- **NCT ID:** NCT04493541
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-26
- **Primary completion:** 2023-04-21
- **Final completion:** 2023-04-21
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2023-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04493541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04493541, "A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus Erythematosus". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04493541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*